XML 59 R49.htm IDEA: XBRL DOCUMENT
v3.26.1

ACQUISITIONS, COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
Jun. 30, 2026 | May 31, 2026 | Apr. 30, 2026 | Jan. 31, 2025 | Jun. 30, 2026 | Jun. 30, 2026 | Jun. 30, 2025
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  |  | $ 12,150 | $ 315
Lakefront |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Percentage share of payment of upfront cash consideration | 50.00% |  |  |  |  |  |
Reduction to acquired in-process research and development expenses |  |  |  |  | $ 860 | $ 860 |
Lakefront | Minimum |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Sales based tired royalty, low-end, percentage | 20.00% |  |  |  | 20.00% | 20.00% |
Lakefront | Maximum |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Sales based tired royalty, high-end, percentage | 23.00% |  |  |  | 23.00% | 23.00% |
LEO Pharma A/S | LEO Pharma A/S Agreement |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Payments to acquire in process research and development |  |  |  | $ 250 |  |  |
Additional payments (up to) |  |  |  | $ 1,500 |  |  |
Ouro Medicines LLC |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Total consideration transferred | $ 1,900 |  |  |  |  |  |
Cash consideration | 1,600 |  |  |  |  |  |
Potential future milestone payments, maximum | 500 |  |  |  | $ 500 | $ 500 |
Acquired in-process research and development expenses |  |  |  |  | 1,900 | 1,900 |
Stock-based compensation expense |  |  |  |  | 135 | 135 |
Ouro Medicines LLC | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  | 45 | 45 |
Ouro Medicines LLC | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  | 91 | 91 |
Ouro Medicines LLC | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesCurrent |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Contingent liability | 143 |  |  |  | 143 | 143 |
Ouro Medicines LLC | Location, Statement of Financial Position, Balance [Axis]: us-gaap:OtherLiabilitiesNoncurrent |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Contingent liability | $ 133 |  |  |  | 133 | 133 |
Tubulis GmbH |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Total consideration transferred |  | $ 3,200 |  |  |  |  |
Potential future milestone payments, maximum |  | $ 1,900 |  |  |  |  |
Acquired in-process research and development expenses |  |  |  |  | 3,100 | 3,100 |
Stock-based compensation expense |  |  |  |  | 51 | 51 |
Tubulis GmbH | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  | 28 | 28 |
Tubulis GmbH | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  | 23 | 23 |
Arcellx, Inc |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Total consideration transferred |  |  | $ 6,400 |  |  |  |
Acquired in-process research and development expenses |  |  |  |  | 7,000 | 7,000 |
Stock-based compensation expense |  |  |  |  | 375 | 375 |
Assets acquired |  |  | 324 |  |  |  |
Liabilities assumed |  |  | 88 |  |  |  |
Settled investments |  |  | $ 773 |  |  |  |
Contingent value right (in dollars per share) |  |  | $ 5 |  |  |  |
Contingent value right, amount |  |  | $ 300 |  |  |  |
Contingent value right, sales threshold |  |  | $ 6,000 |  |  |  |
Arcellx, Inc | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  | 156 | 156 |
Arcellx, Inc | Location, Statement of Income, Balance [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |
Stock-based compensation expense |  |  |  |  | $ 218 | $ 218 |

X
- Definition Asset Acquisition, Consideration Transferred, Contingent Consideration, Range of Outcomes, Maximum, Amount + References No definition available. + Details
Name: | gild_AssetAcquisitionConsiderationTransferredContingentConsiderationRangeOfOutcomesMaximumAmount
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Asset Acquisition, Contingent Value Right, Amount + References No definition available. + Details
Name: | gild_AssetAcquisitionContingentValueRightAmount
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Contingent Value Right, Price Per Share + References No definition available. + Details
Name: | gild_AssetAcquisitionContingentValueRightPricePerShare
Namespace Prefix: | gild_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Asset Acquisition, Minimum Sales Threshold, Grant Of One Contingent Value Right + References No definition available. + Details
Name: | gild_AssetAcquisitionMinimumSalesThresholdGrantOfOneContingentValueRight
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Recognized Asset Acquired, Asset + References No definition available. + Details
Name: | gild_AssetAcquisitionRecognizedAssetAcquiredAsset
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Asset Acquisition, Recognized Liability Assumed, Liability + References No definition available. + Details
Name: | gild_AssetAcquisitionRecognizedLiabilityAssumedLiability
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Percentage Share Of Upfront Payment + References No definition available. + Details
Name: | gild_CollaborativeArrangementPercentageShareOfUpfrontPayment
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Rights And Obligations, Additional Payments + References No definition available. + Details
Name: | gild_CollaborativeArrangementRightsAndObligationsAdditionalPayments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Sales Based Tiered Royalty, High-end, Percentage + References No definition available. + Details
Name: | gild_CollaborativeArrangementSalesBasedTieredRoyaltyHighEndPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Collaborative Arrangement, Sales Based Tiered Royalty, Low-end, Percentage + References No definition available. + Details
Name: | gild_CollaborativeArrangementSalesBasedTieredRoyaltyLowEndPercentage
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Payments For Asset Acquisitions + References No definition available. + Details
Name: | gild_PaymentsForAssetAcquisitions
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Reduction To Research And Development Asset Acquired Due To Payments Received For Upfront Cash Consideration + References No definition available. + Details
Name: | gild_ReductionToResearchAndDevelopmentAssetAcquiredDueToPaymentsReceivedForUpfrontCashConsideration
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized from contingent consideration in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. Includes, but is not limited to, software to be sold, leased, or marketed. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Value of investments transferred from the entity's investments in noncash transactions. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 + Details
Name: | us-gaap_TransferOfInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=gild_LakefrontBiotherapeuticsNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=gild_LEOPharmaASMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_LEOPharmaASAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_OuroMedicinesLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_OtherLiabilitiesCurrent
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_OtherLiabilitiesNoncurrent
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_TubulisGmbHMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=gild_ArcellxIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |